Fertility pioneer introduces benefit programme for employees in Ireland

HRHQ Fertility treatment

by HRHQ Editorial Team

Leading science and technology company, Merck, announced the introduction of a Fertility Benefit Programme in Ireland.

Merck’s Fertility Benefit was first introduced in nine markets in October of 2023, and plans were announced to offer it globally in 2024. This expansion signifies the next step in this journey, as Merck now offers a Fertility Benefit in 20 markets and continues to work at growing this offering across the globe.

The Fertility Benefit is available to eligible employees and their partners, regardless of marital status and sexual orientation. A breadth of services will be covered, such as fertility tests, in vitro fertilisation treatments, and hormonal treatments.

In line with Merck’s efforts to encourage well-being and create an environment where all feel they belong, the company also offers a robust suite of informational resources related to fertility, and has created a dedicated space for a peer support network.

Merck has been making valued contributions to the fertility field for several decades. The company has grown to be the global market leader in therapies for fertility treatment. An estimated five million babies have been born with the help of Merck products. This represents around half of all babies born through medically assisted reproduction since the birth of the first baby conceived through in vitro fertilisation in 1978.